PILA PHARMA Begins Enrollment in Obesity Study
PILA PHARMA has activated its site and enrolled first participants in PP-CT04, a 12-week randomized, double-blind, placebo-controlled obesity study of TRPV1 antagonist XEN-D0501 with individualized dose titration up to 16 mg BID.